45 CFR §46.116; Council for International Organizations of Medical Sciences, International Ethical Guidelines for Biomedical Research Involving Human Subjects (Geneva: World Health Organization, 2002): Guideline 7.
2.
45 CFR 46, supra note 1.
3.
45 CFR 46, supra note 1.
4.
LevineR.J., Ethics and Regulation of Clinical Research, second ed. (New Haven: Yale University Press, 1988): At 82.
5.
Office of Human Research Protection, Protecting Human Research Subjects: Institutional Review Board Guidebook, hereinafter cited as IRB Guidebook (Washington D.C.: U.S. Government Printing Office, XXXX).
6.
GrantR., “The Ethics of Incentives: Historical Origins and Contemporary Understandings,”Economics and Philosophy18(2002): 111–139.
7.
Grant supra note 6;
8.
NewtonL.H., “Inducement, Due and Otherwise,”IRB4, no. 3 (1982): 4–6.
9.
Newton, supra note 7;
10.
LemmensT.ElliottC., “Guinea Pigs on the Payroll: The Ethics of Paying Research Subjects,”Accountability in Research7 (1999): 3–20;
11.
MacklinR., “On Paying Money to Research Subjects,”IRB3, no. 5 (1981):l–6;
12.
FadenR.R.BeauchampT.L., A History and Theory of Informed Consent (New York: Oxford University Press, 1986): Chapter 10.
13.
IRB Guidebook, supra note 5.
14.
CIOMS, supra note 1.
15.
FadenBeauchamp, supra note 8.
16.
Grant, supra note 6
17.
Newton, supra note 7;
18.
LemmensElliot, supra note 7.
19.
McNeillP., “Paying People to Participate in Research: Why Not?”Bioethics11 (1997): 390–96.
20.
FadenBeauchamp, supra note 8;
21.
WertheimerA., Coercion (Princeton, N.J.: Princeton University Press, 1987);
22.
WilkinsonM.MooreA., “Inducement in Research,”Bioethics11 (1997): 373–89.
23.
WertheimerA., Exploitation (Princeton, N.J.: Princeton University Press, 1996): Introduction and chapter 7.
24.
Wertheimer, supra note 15
25.
Participants in 2001 Conference on Ethical Aspects of Research in Developing Countries, “Fair Benefits for Research in Developing Countries,” (hereinafter cited as Fair Benefits) Science298 (2002): 2133–34.
26.
HarrisJ., Wonderwoman and Superman: The Ethics of Human Biotechnology (Oxford: Oxford University Press, 1992): Chapter 6.
27.
LemmensElliot, supra note 8;
28.
Macklin, supra note 8;
29.
Harris, supra note 17;
30.
FeinbergJ., Harm to Self (New York: Oxford University Press, 1986): At 118–121.
31.
Harris, supra note 17;
32.
Feinberg, supra note 18.
33.
EmanuelE.J.WendlerD.GradyC., ,. “What Makes Clinical Research Ethical?”JAMA283 (2000): 2701–11;
34.
EmanuelE.J.WendlerDKillenJGradyC.“What Makes Clinical Research in Developing Countries Ethical? Benchmarks of Ethical Research,”Journal of Infectious Diseases189 (2004).
35.
IRB Guidebook, supra note 5;
36.
EmanuelWendlerGrady, supra note 20.
37.
WilkinsonMoore, supra note 14;
38.
Harris, supra note 17.
39.
WilkinsonMoore, supra note 14.
40.
WilkinsonMoore, supra note 14;
41.
Harris, supra note 17.
42.
Macklin, supra note 8;
43.
McNeill, supra note 13.
44.
Feinberg, supra note 18.
45.
EmanuelE.J.EmanuelL.L., “Four Models of the Physician-Patient Relationship,”JAMA267 (1992): 2221–6.
46.
McNeill, supra note 13.
47.
Harris, supra note 17.
48.
45 CFR46.
49.
WilkinsonMoore, supra note 14;
50.
Harris, supra note 17.
51.
McNeill, supra note 13.
52.
WilkinsonMoore, supra note 14;
53.
Harris, supra note 17.
54.
Feinberg, supra note 18.
55.
McNeill, supra note 13.
56.
Wertheimer, supra note 15.
57.
Wertheimer, supra note 15;
58.
Fair Benefits, supra note 16.
59.
Macklin, supra note 8.
60.
KolataG.B., “NIH Shaken by Death of Research Volunteer,”Science209 (1980): 475–79;
61.
KolataG.B., “The Death of a Research Subject,”Hasting Center Report10, no. 4 ((1980): 5–6.
62.
JonasH., “Philosophical Reflections on Experimenting with Human Subjects,”Daedalus98 (1969): 219–247.
63.
Newton, supra note 7;
64.
LemmensElliot, supra note 7.
65.
EmanuelEmanuel, supra note 27.
66.
Grant, supra note 6;
67.
EmanuelEmanuel, supra note 27.
68.
McNeill, supra note 13.
69.
DickerN.GradyC., “What's the Price of a Research Subject? Approaches to Payment for Research Participation,”N Engl J Med341 (1999):198–203.
